future immune checkpoint therapy 
immune checkpoint therapy targets regulatory pathways t cells enhance antitumor immune responses led important clinical advances provided new weapon cancer therapy elicited durable clinical responses fraction patients long-term remissions patients exhibit clinical signs cancer many years way forward class novel agents lies ability understand human immune responses tumor microenvironment will provide valuable information regarding dynamic nature immune response regulation additional pathways will need targeted combination therapies provide survival benefit greater numbers patients 
